News
First Investment: 2018
EXIT - Nasdaq: ABCL
Antibody therapies represent a blockbuster drug category because they can treat diseases from arthritis to eczema to cancer. But finding antibodies that can be developed into successful new medicines is still a slow, expensive, high-risk process. AbCellera has combined single-cell analysis with modern computation and other tools to create a better search engine for the immune system, allowing rapid identification of therapeutic antibodies against threats such as the SARS-CoV‑2 virus.
News & Insights
News
Confluent IPO: Data In (Upward) Motion
News
Protecting the Digital World Around Us: SentinelOne IPO
News
From Seed to IPO: Zymergen Brings Biofacturing Public
Thoughts
Hermès + MycoWorks: A Match Made in Sustainable Luxury Heaven
News
Evolv Technology, the Leader in AI Touchless Security Screening, to Become Publicly Traded Company
News
Rocket Lab to Become Publicly Traded Commercial Orbital Launch Company
News
Life sciences and Deep Tech: The next set of solutions to the next set of problems
Thoughts
An Update on How Deep Tech is Arming the Fight Against COVID-19
Thoughts
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech
DCVC Announcements
Former Command Senior Enlisted Leader of USSOCOM Patrick McCauley Joins DCVC as Operating Partner
News
Reimagining biologics: AbCellera and Novartis partner to find new disease treatments
News
AbCellera Raises $10M Series A: Deep Search for the Immune System
In The Media
The New Yorker
The New Yorker Explores How AbCellera's Antibody Therapy Treatment May Be the COVID Cure We're Waiting For
AbCellera
Wall Street Journal
Eli Lilly and AbCellera Show Progress for COVID-19 Antibody Therapy Treatment
AbCellera
CNBC
Eli Lilly CEO Talks Partnering with AbCellera Biologics to Co-develop a Coronavirus Cure
AbCellera
Fierce Biotech
AbCellera continues to be a go-to partner for big biopharma antibody discovery efforts, inking new pact with Gilead Sciences
AbCellera
AbCellera Closes Series A led by DCVC Bio
AbCellera
Explore Companies
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery